Abstract
The functions of interleukin-17A (IL-17A) in adipose tissues and adipocytes have not been well understood. In the present study, male mice were fed with a regular diet (n = 6, lean mice) or a high-fat diet (n = 6, obese mice) for 30 weeks. Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were analyzed for IL-17A levels. SAT and VAT were treated with IL-17A and analyzed for inflammatory and metabolic gene expression. Mouse 3T3-L1 pre-adipocytes were differentiated into adipocytes, followed with IL-17A treatment and analysis for inflammatory and metabolic gene expression. We found that IL-17A levels were higher in obese SAT than lean SAT; the basal expression of inflammatory and metabolic genes was different between SAT and VAT and between lean and obese adipose tissues. IL-17A differentially induced expression of inflammatory and metabolic genes, such as tumor necrosis factor α, Il-6, Il-1β, leptin, and glucose transporter 4, in adipose tissues of lean and obese mice. IL-17A also differentially induced expression of inflammatory and metabolic genes in pre-adipocytes and adipocytes, and IL-17A selectively activated signaling pathways in adipose tissues and adipocytes. These findings suggest that IL-17A differentially induces inflammatory and metabolic gene expression in the adipose tissues of lean and obese mice.
Highlights
Obesity is defined as having a body mass index (BMI) ě30 kg/m2 in the adults (>19 years old)
Our study found that obese Subcutaneous adipose tissue (SAT) had higher levels of IL-17A protein than lean SAT, which is consistent to the previous report [20]
We found that the basal levels of Tnf-α, Il-6, and Il-1β were higher in visceral adipose tissue (VAT) than SAT in both lean and obese mice, and the basal levels of Tnf-α, Il-6, and Il-1β were higher in the obese adipose tissues than lean adipose tissues
Summary
Obesity is defined as having a body mass index (BMI) ě30 kg/m2 in the adults (>19 years old). IILL--1177AA ddiiffffeerreennttiiaallllyy iinndduucceess mmeettaabboolliicc ggeennee eexxpprreessssiioonn iinn tthhee aaddiippoossee ttiissssuueess ooff lleeaann aanndd oobbeessee mmiiccee.. ((AA––LL)) AAddiippoossee ttiissssuueess wweerree ccuullttuurreedd iinn sseerruumm--ffrreeee DDMMEEMM aanndd ttrreeaatteedd wwiitthhoouutt (( ́−)) oorr wwiitthh ((++)) 2200 nngg//mmLLILIL-1-177AAfoforr22hh; ;mmRRNNAAeexxpprreessssioionnooffeeaacchhggeenneewwaassaannaalylyzzeeddwwiitthhqqRRTT--PPCCRR;;SSAATT wwiitthhoouutt IILL--1177AAtrtereaatmtmeennt tsesrevrevdedasatshethbeasbaalslaelvelel vfoerl cfoomr cpoamrispoanr;isdoant;a dreaptarerseepnrtemseenatn meSaEnM± (SerErMor (bearrrso)r, bna=rs6),pne=r 6grpoeurpg;r*opup
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
